LRRK2 and Parkinson disease: Together, these results support the exploration of BMP and GSLs as biomarkers of LRRK2-dependent regulation of lysosomal function in ongoing clinical studies and highlight the therapeutic potential of LRRK2 inhibition to correct lysosomal dysfunction observed in PD.